← Back to Search

Unknown

Intervention 1 for Epilepsy

Phase 1
Waitlist Available
Research Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 days
Awards & highlights

Study Summary

This trial is testing a new medication to see if it can help people with epilepsy who haven't been helped by other medications.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Standardized Photosensitivity Range (SPR)
Secondary outcome measures
Onset and duration of SPR

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Intervention 1Experimental Treatment2 Interventions
Single dose; up to 400 mg capsule; adaptive dosage determined by initial dosing from cohort 1.Potential for a matching placebo dose to be administered.
Group II: PlaceboPlacebo Group2 Interventions
Single dose; potential for a matching OPC-214870 dose to be administered.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
OPC-214870
2020
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor
246 Previous Clinical Trials
167,153 Total Patients Enrolled
~3 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top